<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611102</url>
  </required_header>
  <id_info>
    <org_study_id>404482-2</org_study_id>
    <nct_id>NCT02611102</nct_id>
  </id_info>
  <brief_title>Effect of Butter &amp; MCT Oil on Lipoproteins - A RCT</brief_title>
  <official_title>Effects of Daily Butter &amp; Medium-Chain Triglyceride Oil on Lipoproteins When Added to Baseline Diet a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed National Military Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Reed National Military Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the effects on lipoprotein profiles of high dose concentrated dietary SFA&#xD;
      (saturated fatty acids) (from MCT (medium-chain triglyceride) oil + butter) in combination&#xD;
      added to coffee. The study will be conducted as a RCT in healthy adults without&#xD;
      cardiometabolic disease or conditions that influence lipoprotein metabolism or other specific&#xD;
      dietary recommendations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Design A prospective randomized controlled interventional study&#xD;
&#xD;
      Methodology /Technical Approach A total of up to 60 subjects will be recruited to allow for&#xD;
      completion of the study by a minimum of 17 subjects per arm. Subjects will be randomized to&#xD;
      one of two groups in a 1:1 ratio. Recruited subjects will be adult coffee drinkers between&#xD;
      the ages of 18-45 without hyperlipidemia and without criteria for diabetes or pre-diabetes.&#xD;
      Subjects will have baseline weight, waist circumference (WC), and blood-pressure (BP)&#xD;
      measurements obtained. Subjects will have baseline fasting lipids,, CMP,HbA1c,TSH,and hsCRP.&#xD;
      The subjects will be stratified by gender and randomized to receive one of two dietary&#xD;
      regimens: 1) coffee (&lt; 50 kcal of added creamer/sweetener) or 2) coffee with butter +&#xD;
      medium-chain triglyceride (MCT) oil combination (2 tbsp. MCT containing 230kcal and 28gm fat+&#xD;
      2 tbsp butter containing 200kcal and 22gm fat). The drink will be consumed daily over a 4&#xD;
      week period. Dietary history will be evaluated by via the ASA24website&#xD;
      (http://appliedresearch.cancer.gov/asa24/). At 6 and 12 weeks post-consent, baseline labs&#xD;
      will be repeated. The primary outcome is change in apolipoprotein B between groups. Secondary&#xD;
      outcomes include changes in lipids, WC, BP, HbA1c, and FBG. Exploratory analysis will include&#xD;
      changes in dietary macronutrient load and subgroup analysis of effects related to dietary&#xD;
      patterns.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      1. Evaluate clinically and statistically significant changes of apoB number in healthy adults&#xD;
      who consume coffee with butter and MCT oil.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      1. Evaluating change in:&#xD;
&#xD;
        1. non-HDL-c&#xD;
&#xD;
        2. LDL-c&#xD;
&#xD;
        3. triglycerides&#xD;
&#xD;
        4. BP&#xD;
&#xD;
        5. waist circumference&#xD;
&#xD;
        6. FBG&#xD;
&#xD;
        7. HbA1c&#xD;
&#xD;
      Exploratory objective:&#xD;
&#xD;
      1. Change in macronutrient profiles of dietary patterns.&#xD;
&#xD;
      Our null hypothesis is that the addition of butter and medium-chain triglyceride oil at&#xD;
      proposed doses has no clinically significant effects on atherogenic lipoproteins, namely apo&#xD;
      lipoprotein B particles (apoB).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in apolipoprotein B</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>non-HDL-c</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-c</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglycerides</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>MCT oil + Butter in Coffee</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be provided with MCT oil and butter to add to their daily coffee intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low calorie coffee</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will continue to drink their normal daily coffee with &lt; 50kcal of creamer and/or sweetener.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MCT oil + Butter in Coffee</intervention_name>
    <description>2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.</description>
    <arm_group_label>Low calorie coffee</arm_group_label>
    <arm_group_label>MCT oil + Butter in Coffee</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. DoD healthcare beneficiaries&#xD;
&#xD;
          2. willing to drink 2 to 4 cups of coffee daily&#xD;
&#xD;
          3. between the ages of 18 to 45&#xD;
&#xD;
          4. serum LDL-c &lt; 160,&#xD;
&#xD;
          5. non-HDL-c &lt; 190&#xD;
&#xD;
          6. apoB &lt; 120&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BMI &gt; 30kg/m2 or &lt; 20kg/m2 or waist circumference &gt; 102cm (males) or 88cm (females)&#xD;
&#xD;
          2. Triglycerides &gt; 150&#xD;
&#xD;
          3. Hypertension defined as SBP &gt; 150, DBP &gt; 90 or on treatment for high blood pressure&#xD;
&#xD;
          4. Chronic liver disease defined by any clinical or a history of serum AST or ALT &gt; 3&#xD;
             times ULN&#xD;
&#xD;
          5. Kidney disease defined as a GFR &lt;90 ml/min or history of nephritic syndrome&#xD;
&#xD;
          6. Impaired glucose metabolism defined as HbA1c &gt; 5.6, FBG &gt; 99, or 2-hour OGTT &gt; 139&#xD;
&#xD;
          7. Any known malignancy&#xD;
&#xD;
          8. Known malabsorption disorder to include inflammatory bowel disease, celiac disease,&#xD;
             cystic fibrosis, history of gastric bypass&#xD;
&#xD;
          9. Hypothyroidism per lab evaluation at baseline&#xD;
&#xD;
         10. Pregnancy&#xD;
&#xD;
         11. Polycystic Ovary Syndrome or irregular menstrual periods&#xD;
&#xD;
         12. Subjects taking certain medications such as glucocorticoids, immunosuppressants&#xD;
             (cyclosporine, sirolimus, etc.), tamoxifen, androgens, antipsychotics,&#xD;
             hydrochlorothiazide, retinoids, beta-blockers, statins, bile acid sequestrants,&#xD;
             niacin, fibrates, ezetimibe, high dose fish oil (&gt;1gm/day epa + dha), or any other&#xD;
             supplement or pharmacologic agent known to alter lipoproteins&#xD;
&#xD;
             a. If on hormonal contraceptives, lipid panel must be stable over the past 12-24&#xD;
             months&#xD;
&#xD;
         13. Cushing's syndrome per medical history or clinical suspicion&#xD;
&#xD;
         14. HIV per medical history&#xD;
&#xD;
         15. Chronic Inflammatory Disorders such as, but not limited to, SLE, RA, IBD per medical&#xD;
             history&#xD;
&#xD;
         16. History of tobacco use within the previous 12 months to include cigarettes,&#xD;
             e-cigarettes, chewing tobacco, cigars, and pipes.&#xD;
&#xD;
         17. History of marijuana use within the previous 12 months&#xD;
&#xD;
         18. Active intentional weight loss of over 5% in the past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thanh D Hoang, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>WRNMMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thanh D Hoang, DO</last_name>
    <phone>301-295-6220</phone>
    <email>thanh.d.hoang.mil@mail.mil</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Iris E Robbins, BA</last_name>
    <phone>301-319-2869</phone>
    <email>iris.e.robbins1.civ@mail.mil</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889-5600</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanh D Hoang, MD</last_name>
      <phone>301-295-6220</phone>
      <email>thanh.d.hoang.mil@mail.mil</email>
    </contact>
    <contact_backup>
      <last_name>Iris E Robbins, BA</last_name>
      <phone>301-319-2869</phone>
      <email>iris.e.robbins1.civ@mail.mil</email>
    </contact_backup>
    <investigator>
      <last_name>Karl Z Nadolsky, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thanh D Hoang, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

